Sandoz is a global leader in generics and biosimilars, a division of the Novartis Group. Our mission is to find new ways to improve the quality and length of people's lives. Sandoz's mission is to open up new opportunities for access to high-quality medicine for people around the world, helping society to meet the growing needs of healthcare.

The company's product portfolio consists of more than 1,000 molecules covering all major therapeutic areas of medicine. The company's broad product line enables patients and healthcare organizations to significantly reduce costs in the long term. This contributes to the sustainability of health systems by reducing the financial burden and freeing up funds for the development of innovative medicines.

Our preparations are represented in the markets of more than 160 countries of the world. They are already used by more than 500 million patients, and we aim to increase the number of patients to one billion. A special place in our diversified portfolio of about 1,000 molecules is occupied by biosimilars - advanced generic biologicals, as well as antibiotics, drugs that are indispensable for the functioning of the global health system.

We implement a number of targeted programs in the field of corporate social responsibility, focused on the most needy groups of the population. These initiatives are aimed at meeting the needs of socially unprotected categories of the population in medical care, expanding access to medical information and creating conditions for the development of medicine.

Sandoz's sales in 2016 were $10.1 billion. The headquarters is located in Holzkirchen (Germany).

The Council of Experts in Nephrology was held in St. Petersburg with the support of Sandoz

The topic of the Council is "Scientific and practical approaches to overcome resistance to erythropoiesis-stimulating therapy in patients with anemia in chronic kidney disease."
The meeting of the Council of Experts was attended by leading experts in the field of nephrology in Russia and foreign experts.

One of the important factors in the pathogenesis of renal anemia is a decrease in the production of endogenous erythropoietin, a hormone that stimulates the erythrocyte link of hematopoiesis. The introduction of recombinant erythropoietin (EPO) preparations into clinical practice in 1987 fundamentally changed the treatment strategy and outcomes of anemia in patients with CKD.

However, despite the use of high-tech methods of treatment - erythropoiesis-stimulating drugs (ESP), the achievement of target hemoglobin levels is not always possible. Approximately 10-20% of patients with renal anemia show decreased response or resistance to ESP treatment. Such resistance is predictive of poor prognosis and increased mortality of any etiology, regardless of other risk factors. The problem of reduced response to ESP therapy is not given enough attention in the current clinical guidelines and needs to be improved.

Prevention and treatment of calcium deficiency; prevention and treatment of osteoporosis (in complex therapy); treatment of rickets and osteomalacia (in combination therapy with vitamin D3).

Pharmacotherapeutic group

Calcium-phosphorus metabolism regulator.

Pharmacological property

Calcium is a vital mineral element necessary for maintaining the balance of electrolytes in the body and the adequate functioning of numerous regulatory mechanisms. Compensates for Ca2+ deficiency in the body, participates in phosphate-calcium metabolism, has vitamin, anti-rachitic, anti-inflammatory and anti-allergic effects. Calcium Sandoz Forte contains two calcium salts (calcium lactogluconate and calcium carbonate), which in the form of effervescent tablets quickly dissolve in water, turning into an active ionized form of calcium, which is easily absorbed. This dosage form provides an adequate supply of calcium to the body in the form of a tasty drink and is intended for the prevention and treatment of acute and chronic calcium deficiency in the body, as well as for the treatment of various types of metabolic disorders in bone tissue.

Contraindications

Hypersensitivity to the components of the drug, increased calcium concentration in the blood and urine (hypercalcemia, hypercalciuria), chronic renal failure, nephrourolithiasis, nephrocalcinosis, phenylketonuria and sucrose / isomaltose deficiency, fructose intolerance, glucose-galactose malabsorption. Calcium Sandoz Forte is not recommended for use in children under the age of 3 years due to the lack of data on efficacy and safety in this category.

Application

Inside, regardless of the meal. Before taking the tablet, dissolve it in a glass of water. Children from 3 to 9 years: 500 mg per day. Adults and children from 10 years: 1000 mg per day. : when used for the prevention and treatment of calcium deficiency, the average duration of the course of treatment is at least 4-6 weeks; when used for the prevention and treatment of osteoporosis, the treatment of rickets and osteomalacia, the duration of treatment is determined individually.

Side effects

Immune system disorders: rarely: hypersensitivity reactions, incl. rash, itching, urticaria; very rarely: in isolated cases, systemic allergic reactions (such as anaphylactic reactions, swelling of the face, angioedema) have been reported. Metabolic and nutritional disorders: infrequently: hypercalcemia, hypercalciuria. Gastrointestinal disorders: rarely: flatulence, constipation, diarrhea, nausea, vomiting, abdominal pain. When taken in high doses (2000 mg / day when taken daily for several months), headache, fatigue, thirst, polyuria may occur.

Overdose

Overdose leads to the development of hypercalciuria and hypercalcemia. Symptoms of hypercalcemia: nausea, vomiting, thirst, polydipsia, polyuria, dehydration and constipation. Chronic overdose with the development of hypercalcemia can lead to liming of blood vessels and organs. The threshold of calcium intoxication - when taking calcium preparations for several months at a dose exceeding 2000 mg / day. Therapy in case of overdose In case of intoxication, therapy should be stopped immediately and the water and electrolyte balance restored. In chronic overdose, if signs of hypercalcemia are detected, hydration is carried out at the initial stage with a 0.9% sodium chloride solution. Loop diuretics, such as furosemide, can be used to enhance calcium excretion and to avoid tissue edema (eg, in congestive heart failure). In this case, you should refrain from using thiazide diuretics. In patients with renal insufficiency, hydration is ineffective, dialysis is indicated for such patients. In the case of persistent hypercalcemia, other factors contributing to its development should be excluded, including hypervitaminosis of vitamin A or D, primary hyperparathyroidism, malignant tumors, renal failure, stiffness of movements.

Interaction with other drugs

The combination of calcium carbonate + calcium lactogluconate may reduce the absorption of estramustine, etidronate and possibly other bisphosphonates, phenytoin, quinolones, oral tetracycline antibiotics and fluoride preparations. The interval between taking effervescent calcium carbonate + calcium lactogluconate tablets and the above drugs should be at least 3 hours. The simultaneous administration of vitamin D and its derivatives increases calcium absorption. When administered in high doses along with vitamin D and its derivatives, calcium may reduce the effect of verapamil and possibly other calcium channel blockers. With the simultaneous use of effervescent calcium carbonate + calcium lactogluconate tablets and tetracycline preparations, the absorption of the latter may be impaired. For this reason, tetracycline preparations should be taken at least 2 hours before or 4-6 hours after ingestion of calcium supplements. Thiazide diuretics reduce urinary calcium excretion, therefore, when they are used simultaneously with calcium carbonate + calcium lactogluconate effervescent tablets, regular monitoring of calcium concentration in the blood serum should be carried out, since there is a risk of developing hypercalcemia. Systemic corticosteroids reduce calcium absorption. With their simultaneous use, it may be necessary to increase the dose of calcium carbonate + calcium lactogluconate effervescent tablets. When ingested tablets of effervescent calcium carbonate + calcium lactogluconate in patients receiving cardiac glycosides, an increase in the toxicity of cardiac glycosides due to the development of hypercalcemia is possible. Such patients should regularly take an ECG and monitor the level of calcium in the blood serum. When bisphosphonate or sodium fluoride is taken orally at the same time, these drugs should be taken at least 3 hours before calcium carbonate + calcium lactogluconate effervescent tablets, since absorption from the gastrointestinal tract (GIT) of bisphosphonate or sodium fluoride may decrease. Calcium absorption from the gastrointestinal tract may decrease with the simultaneous intake of certain types of food containing oxalic acid (for example, spinach, rhubarb) or phytic acid (in all grains) due to the formation of insoluble complexes with calcium ions. Patients should not take calcium carbonate + calcium lactogluconate effervescent tablets 2 hours before or after eating a meal rich in oxalic or phytic acid.

Company Sandoz, the generics division of the Novartis group of companies, is a leader in the rapidly growing generics industry. Sandoz offers about 1,100 high-quality, affordable drugs that are out of patent protection. With over 26,000 employees in 140 countries Sandoz occupies a leading position in the world both in the field of biosimilars, in the market for injectable, ophthalmic, dermatological drugs, as well as 5th place among manufacturers of inhaled drugs. The group of the company's most significant pharmaceutical products includes antibiotics, medicines for the treatment of diseases of the cardiovascular and central nervous systems, the gastrointestinal tract, and hormone therapy. Company Sandoz develops, manufactures and markets medicines, as well as pharmaceutical, biotechnological active ingredients and antibiotics. In addition to strong growth in recent years, the company Sandoz made a number of acquisitions, including Lek (Slovenia), Sabex (Canada), Geksal (Germany), Eon Labs (USA), Ebewe Pharma (Austria), Oriel Therapeutics (USA) and Fugera Pharmaceuticals (USA). In 2012, net sales reached US$8.7 billion.

Main therapeutic areas

Anti-infectives

The cardiovascular system

Blood and hematopoietic organs

Digestive system and endocrinological disorders

central nervous system

Anticancer and immunomodulatory agents

Respiratory system

Dermatological products

Ophthalmic products

A differentiated portfolio of drugs provides additional benefits

Biosimilars – high-quality, clinically proven alternatives to existing biologics with comparable safety and efficacy at a more affordable price. Sandoz is a pioneer and world leader with three marketed products that are top sellers in their therapeutic areas (G-CSF, EPO, Human Growth Hormone).

Injectable drugs - non-biological drugs, administered by injection, which are available modern generic drugs. Company Sandoz ranked first in this field since 2011.

Inhalation drugs – sophisticated drugs and high-tech delivery devices to meet the rapidly growing demand for affordable new drugs for the treatment of bronchial asthma and COPD (chronic obstructive pulmonary disease) in a complex regulatory environment. Company Sandoz strive to take a leading position in this direction in order to further strengthen its position along with other strategic directions.

Ophthalmic preparations - high-quality medicines aimed at correcting anatomical, physiological conditions and fighting eye diseases. With the acquisition of a wide range of generic ophthalmic products from the Falcon division, the company Sandoz has become a world leader in this field.

Dermatological preparations - drugs based on rich experience in development and production and intended for the treatment of dermatological diseases, including drugs in semi-liquid forms (creams and ointments), as well as more than 60 FDA (Food and Drug Administration) approved drug names for various therapeutic groups of the PharmaDerm division in the USA. Through the acquisition of Fuger Pharmaceuticals, the company Sandoz is a world leader in generic dermatological products.

> Sandoz / Sandoz, CJSC (Moscow)

This information cannot be used for self-treatment!
Be sure to consult with a specialist!

The international pharmaceutical company Sandoz / Sandoz, which has been supplying its products to the market for more than a century, is today one of the world leaders in the production of quality generics. The range of the company's drugs is represented by solid, liquid and soft dosage forms and covers almost all pharmacotherapeutic groups.

The headquarters of Sandoz is located in the German city of Holzkirchen in Bavaria. The company's production units are located on the European continent, as well as in the USA, Canada, Argentina, and India. Over the past decade, the Sandoz manufacturing base has expanded through the acquisition of companies such as Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs and Oriel Therapeutics (USA), EBEWE Pharma (Austria).

The Russian division is represented by CJSC Sandoz, which promotes the company's products on the Russian market. About 60 types of drugs are sold in Russia, and in 2017, with the launch of a new modern plant near St. Petersburg, their list will expand significantly.

Sandoz manufactures:

• tableted antibiotics of various groups Abaktal, Amoxiclav, Amoxicillin Sandoz, including in dispersible tablets Amoxiclav Quiktab;


• parenteral antibiotics Abaktal, Amoxiclav, Cefazolin Sandoz, Lendacin;


• antihypertensive tablet monopreparations Amlodipine Sandoz, Biol, Carvedilol Sandoz, Doxazosin Sandoz, Lozarel, Moxonitex, Nifecard and combination remedy Atenolol compositum Sandoz;


• antiviral agent Aciclovir Sandoz in the form of a cream for the treatment of skin manifestations of a herpes infection;


• mucolytics for adults and children ACC, ACC 100, ACC 200, ACC 400, ACC long in granules and effervescent tablets, as well as ACC injection in ampoules, facilitating coughing in violation of the discharge of bronchial secretions;


• antibacterial external agent containing two antibiotics, Baneocin in powder and ointment form for the treatment of bacterial skin lesions sensitive to the drug;


• antianemic drug in injection solution Binocrit- a stimulator of the formation and accelerated maturation of erythrocytes in the bone marrow;


• immunostimulants Broncho-munal, Broncho-munal P in capsules, activating the immune defense when it is reduced as a result of infectious lesions of the respiratory tract;


• external venotonic gel Venitan, cream Venitan N with horse chestnut extract and combined preparation Venitan forte in the form of a gel for the treatment of pathology of the saphenous veins;


• enzyme preparation Gastenorm forte, containing the main digestive enzymes, to facilitate the work of the pancreas;


• antiparkinsonian drug On whom providing subsidence of the severity of the clinical symptoms of the disease;


• intestinal biocenosis regulator Linex in capsules with high probiotic activity;


• herbal antidepressants Deprim in the form of tablets and Deprim forte in capsules with a mild sedative effect;


• antibacterial dermatological cream Dermazin with active silver for wound healing;


• external analgesic Diklak in the form of a gel, effective for radiculitis, myositis, superficial injuries;


• tableted non-steroidal drug Diclofenac Sandoz for the treatment of pain and swelling of an inflammatory nature;


• anti-inflammatory nonsteroidal drugs in tablets Ketonal, Ketonal uno, Ketonal duo, as well as Ketonal thermo in the form of a patch with a pronounced analgesic effect;


• hemostatic agent Dicynon in tablets and ampoules for the treatment of all types of bleeding;


• antifungal drug for systemic treatment of candidiasis Fluconazole Sandoz in capsules;


• herbal remedy Immunal in tablets and oral solution to stimulate immune defenses;


• antiallergic agent Lomilan in tablets and oral suspension form;


• symptomatic antidiarrheal agent Lopedium in capsules and tablets;


• anti-ulcer agent in capsules Omeprazole Sandoz, which reduces the acidity of the stomach;


• antifungal cream and topical solution Exoderil for the treatment of fungal infections of the skin.

Kristina

Senior Drug Manager, Cardiology Business Unit

Almost one in ten in Russia suffers from chronic heart failure, but not everyone knows about it. I am proud that in my role I can raise awareness of the disease, and the use of digital technologies allows to reach more patients.

Svetlana

Head of Medical Consultants

Over 14 years. I became a doctor to help people. By joining Novartis, I can help fight cancer for far more patients than in practical medicine.

Julia

Head of the Department of Clinical Research of Pharmaceuticals

More than 2,000 Russian patients are participating in international clinical trials. I am proud to work for a company that invests in the development of innovative drugs that change patients' lives for the better.

Vladimir

Research Director

5 positions in 3 countries in 9 years. Working with an innovative portfolio of medicines and great career opportunities inspire me to continue working at Novartis.

Love

Head of Human Resources Department

15 years in the company. During this time, I managed to change 6 positions and gain experience in all divisions. I am pleased to be a member of the HR team. I am here to create an environment in which our employees reach their potential and change the way they approach medicine for the benefit of our patients.

Olga

Senior Regional Manager of the Department for the Promotion of Cardiology Products

The number of patients with cardiovascular diseases that we help is measured in thousands.
I am inspired by the fact that with my daily work I help them to increase the duration and improve the quality of life.

Anna

Head of Department Neurology

Over 5 years with Novartis. The scale and resources of the company allow us to provide more patients with the therapy they need, while at the same time giving us the opportunity to develop in a culture of support and cooperation. This is one of the reasons that inspires me to work at Novartis.

Julia

Director of the Ophthalmic Business Unit

More than 3 years at Novartis I never tire of being proud of what a great company I work for! It is important for us to reveal the talent of each employee. Novartis has a very special atmosphere in which you want to grow and become better!